Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
An antiprotozoal agent, a derivative of 5-nitroimidazole. It is believed that the mechanism of action is associated with a violation of the structure of DNA of sensitive microorganisms. It is active against Trichomonas vaginalis, Giardia lamblia, Entamoeba histolytica, and also for some anaerobic bacteria (including Bacteroides spp., Clostridium spp., Fusobacterium and anaerobic cocci).
T 1/2 of ornidazole is greater than that of metronidazole.
PHARMACOKINETICS
After ingestion, absorption from the gastrointestinal tract is high. The time to reach C max is 1-2 h.
Binding to plasma proteins is 15% or more. Penetrates through the BBB. T 1/2 - about 13 hours.
It is excreted as metabolites by the kidneys (60-70%) and with feces (20-25%), in unchanged form - about 5%.
INDICATIONS
Trichomoniasis, amoebiasis (intestinal and non-intestinal forms, including amoebic dysentery and amoebic liver abscess), giardiasis, prevention of postoperative complications (especially in operations on the colon or in gynecology).
DOSING MODE
For oral administration, depending on the indications, treatment regimens and body weight of the patient, a single dose for adults varies from 500 mg to 2 g; for children weighing up to 35 kg daily dose is 20-40 mg / kg. Multiplicity of reception and duration of application are set individually.
In the form of intravenous infusions in adults used in the initial dose of 0.5-1 g, then the dose is set individually, depending on the indications and treatment regimen;for children - 20-30 mg / kg / day.
SIDE EFFECT
From the digestive system: possible - nausea, heartburn, dizziness, drowsiness, skin rash.
From the nervous system: possible - headache, dizziness, impaired consciousness, tremor, rigidity of muscles, impaired coordination of movements, convulsions, sensory or mixed peripheral neuropathy, nausea, vomiting, diarrhea.
CONTRAINDICATIONS
Central nervous system diseases, acute neurological diseases, I trimester of pregnancy, lactation period, hypersensitivity to ornidazole.
PREGNANCY AND LACTATION
Contraindicated in the first trimester of pregnancy, during lactation. In pregnancy, use is only possible on absolute indications, if the expected benefit for the mother exceeds the potential risk to the fetus.
APPLICATION FOR CHILDREN
The application is possible according to the dosing regimen.
SPECIAL INSTRUCTIONS
Does not inhibit alcohol dehydrogenase, therefore it is not incompatible with alcohol.
DRUG INTERACTION
Potentiates the effect of indirect anticoagulants, increases the duration of action of vecuronium bromide.
